Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIT-HARD: short-course high-dose versus conventional antibiotic therapy in critically ill adults with severe bacterial infection
NL-OMON60272Phase 3Recruiting
- Sponsor
- Ghent University Hospital
- Start
- Jul 2025
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ceftriaxone, cefotaxime, cefuroxime, piperacillin + tazobactam and meropenem in pneumonia, Intra-abdominal infection (IAI) and bloodstream infection (BSI), sponsored by Ghent University Hospital. Started Jul 2025; status: recruiting.
02
Drugs
ceftriaxonecefotaximecefuroximepiperacillin + tazobactammeropenem
03
Conditions
pneumoniaIntra-abdominal infection (IAI)bloodstream infection (BSI)
Beyond the preview
Go deeper on NL-OMON60272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60272.